NASDAQ · ANTX
Healthcare · Biotechnology
$5.89
Down-$0.06 (-1.01%)
Updated Sep 6, 2026, 11:18 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ANTX closed at $5.89 after 20 trading sessions, down 0.34% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $5.97 | $6.06 | $5.85 | $5.89 | 77.18K |
| Sep 3, 2026 | $6.05 | $6.20 | $5.79 | $5.95 | 199.66K |
| Sep 2, 2026 | $5.46 | $6.00 | $5.46 | $5.95 | 353.56K |
| Sep 1, 2026 | $5.53 | $5.67 | $5.40 | $5.48 | 215.42K |
| Aug 31, 2026 | $5.58 | $5.645 | $5.40 | $5.55 | 124.02K |
| Aug 28, 2026 | $5.67 | $5.78 | $5.40 | $5.58 | 240.87K |
| Aug 27, 2026 | $5.46 | $5.79 | $5.46 | $5.74 | 204.04K |
| Aug 26, 2026 | $5.66 | $5.85 | $5.50 | $5.53 | 287.52K |
| Aug 25, 2026 | $5.67 | $5.80 | $5.60 | $5.66 | 217.71K |
| Aug 24, 2026 | $5.82 | $5.82 | $5.59 | $5.63 | 171.42K |
| Aug 21, 2026 | $5.84 | $5.89 | $5.50 | $5.81 | 225.45K |
| Aug 20, 2026 | $5.98 | $6.13 | $5.72 | $5.79 | 195.34K |
| Aug 19, 2026 | $5.97 | $6.045 | $5.7747 | $5.96 | 266.09K |
| Aug 18, 2026 | $5.59 | $5.995 | $5.58 | $5.97 | 215.7K |
| Aug 17, 2026 | $5.96 | $6.21 | $5.725 | $5.73 | 273.77K |
| Aug 14, 2026 | $6.04 | $6.205 | $5.94 | $5.99 | 198.35K |
| Aug 13, 2026 | $6.28 | $6.365 | $5.90 | $5.98 | 298.93K |
| Aug 12, 2026 | $6.09 | $7.19 | $5.66 | $6.28 | 429.2K |
| Aug 11, 2026 | $5.92 | $6.09 | $5.8001 | $5.87 | 68.73K |
| Aug 10, 2026 | $5.91 | $6.08 | $5.69 | $5.91 | 91.25K |
The latest Smart Investors Daily articles mentioning ANTX.
ANTX research
Company profile and research snapshot.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 20, 2026 | Guggenheim | Buy | — |
| May 14, 2026 | Leerink Partners | Outperform | — |
| May 5, 2025 | JMP Securities | Market Outperform | — |
| Mar 26, 2025 | Citizens Capital Markets | Market Outperform | — |
| Feb 25, 2025 | Citizens Capital Markets | Market Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 31, 2026
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced
Benzinga · Aug 11, 2026
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 14.29 percent increase over losses of $(0.21) per share from
Benzinga · Jul 20, 2026
Guggenheim analyst Brad Canino initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Buy rating and announces Price Target of $9.
Yahoo · Jun 4, 2026
MENLO PARK, Calif., June 04, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) caused by infection with the parasite T. cruzi.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANTX.
